Recent Quotes (30 days)

You have no recent quotes
chg | %

Theralase Technologies Inc.  

(Public, CVE:TLT)   Watch this stock  
Find more results for TLT
+0.005 (1.08%)
Oct 20 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.46 - 0.47
52 week 0.17 - 0.55
Open 0.47
Vol / Avg. 0.00/161,055.00
Mkt cap 59.45M
P/E     -
Div/yield     -
EPS -0.05
Shares 126.48M
Beta 0.05
Inst. own     -

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -346.71% -256.46%
Operating margin -346.71% -256.46%
EBITD margin - -247.92%
Return on average assets -153.91% -73.77%
Return on average equity -175.04% -81.97%
CDP Score - -


1945 Queen St E
+1-416-6995273 (Phone)
+1-416-6995250 (Fax)

Website links


Theralase Technologies Inc. is a biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (PDCs) to destroy cancer. The Company operates through two divisions: Therapeutic Laser Technology (TLT) division and Photo Dynamic Therapy (PDT) division. The TLT division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology is used for healing a range of nerve, muscle and joint conditions, including arthritis, osteoarthritis and wounds. The PDT division develops PDCs and activates them with laser technology to destroy specifically targeted cancers and bacteria. Its TLC-2000 Biofeedback Therapeutic Laser Technology possesses Cell Sensing technology that senses and targets injured tissue. It is also developing TLC-1000 therapeutic medical laser system. It is developing TLC-3000 medical laser system for the treatment of a range of cancers.

Officers and directors

Roger Dumoulin-White President, Chief Executive Officer, Director
Kristina Hachey Chief Financial Officer
Michael Borovec Director of Investor Relations
Matthew Perraton Director
Guy John Anderson Independent Director
Age: 1
Randall Bruder Independent Director